Enzo Biochem, Inc.

Equities

ENZ

US2941001024

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
1.05 ^USD	-1.87%		-3.67%	-24.46%

Mar. 15	North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	DJ
Mar. 13	Enzo Biochem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

Enzo Biochem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023

June 14, 2023 at 05:14 pm EDT

Enzo Biochem, Inc. reported earnings results for the third quarter and nine months ended April 30, 2023. For the third quarter, the company reported sales was USD 16.11 million compared to USD 26.22 million a year ago. Net loss was USD 15.19 million compared to USD 4.85 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.1 a year ago.
For the nine months, sales was USD 50.72 million compared to USD 86.79 million a year ago. Net loss was USD 37.14 million compared to USD 9.83 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 0.2 a year ago.

Latest news about Enzo Biochem, Inc.

North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	Mar. 15	DJ
Enzo Biochem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 13	CI
Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer	Feb. 01	CI
Enzo Biochem, Inc. Appoints Patricia Eckert as Chief Financial Officer	Feb. 01	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
North American Morning Briefing : Stock Futures Edge Up to Start the Week	Dec. 18	DJ
Enzo Biochem, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 15	CI
North American Morning Briefing : Traders Await -2-	Dec. 13	DJ
North American Morning Briefing : Investors Weigh -2-	Nov. 10	DJ
Enzo Biochem, Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 03	CI
Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors	23-10-30	CI
North American Morning Briefing : Amazon, Intel -2-	23-10-27	DJ
North American Morning Briefing : Bond Yields, -2-	23-10-20	DJ
North American Morning Briefing : Stock Futures Point Lower Ahead of Big Bank Earnings	23-10-13	DJ
Enzo Biochem Chief Executive Hamid Erfanian Departs	23-09-06	MT
Enzo Biochem Announces Departure of Hamid Erfanian from the Board of Directors	23-09-06	CI
Enzo Biochem, Inc. Announces CEO Changes	23-09-06	CI
Top Premarket Gainers	23-07-25	MT
Enzo Biochem Completes Deal to Sell Clinical Laboratory Division to Laboratory Corp. of America for $113.3 Million	23-07-24	MT
North American Morning Briefing : Traders Digest -2-	23-06-15	DJ
Enzo Biochem, Inc. Reports Revenue Results for the Third Quarter Ended April 30, 2023	23-06-14	CI
Enzo Biochem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14	CI
North American Morning Briefing : Nasdaq Futures Slip as Rate Rise Fears Weigh	23-06-08	DJ
Enzo Biochem, Inc. announced that it expects to receive $7.608696 million in funding from JGB Collateral, LLC	23-05-18	CI
Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027	23-05-08	CI

Chart Enzo Biochem, Inc.

Duration

Period

More charts

Company Profile

Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.

Sector

Biotechnology & Medical Research

Calendar

2024-06-09 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENZO BIOCHEM, INC.	-24.46%	53.79M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research